3-(4-amino-2-methyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-(4-amino-2-methyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 3-(4-amino-2-methylphenoxy)piperidine-1-carboxylate
• 化学式: C₁₇H₂₆N₂O₃
• 分子量: 306.405
• InChiKey: RMEWHIAMGZSGHY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  64.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-BOC-3-羟基哌啶 在 palladium dihydroxide 氢气 、 sodium hydride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 10.0~20.0 ℃ 、310.27 kPa 条件下， 反应 16.5h， 生成 3-(4-amino-2-methyl-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer

  摘要：

  The synthesis and biological evaluation of potent and selective inhibitors of the erbB2 kinase is presented. Based on the 4-anilinoquinazoline chemotype, the syntheses of several new series of erbB2 inhibitors are described with quinazoline and pyrido[4,3-d]pyrimidine cores. The vast majority of these compounds are found to be >100x selective over the closely related EGFR kinase. Two lead compounds are further shown to have low clearance and moderate bioavailability in rat. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.046

文献信息

• Substituted heterocycles for the treatment of abnormal cell growth
  申请人：Pfizer Inc

  公开号：US20040242604A1

  公开（公告）日：2004-12-02

  The invention relates to compounds of formula 1 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 3 , R 4 , R 11 , N, Z, A, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  该发明涉及公式11的化合物以及其药学上可接受的盐、前药和溶剂化合物，其中R1、R3、R4、R11、N、Z、A、m和p如本文所定义。该发明还涉及通过给予公式1的化合物来治疗哺乳动物中的异常细胞生长的方法，以及用于治疗这类疾病的含有公式1的药物组合物。该发明还涉及制备公式1的化合物的方法。
• [EN] QUINAZOLINES AND PYRIDO [3,4-D] PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS<br/>[FR] QUINAZOLINES ET PYRIDO[3,4-D] PYRIMIDINES UTILISES COMME INHIBITEURS DE RECEPTEURS TYROSINE KINASE
  申请人：PFIZER PROD INC

  公开号：WO2004106308A1

  公开（公告）日：2004-12-09

  The invention relates to compounds of formula 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R1, R3, R4, R11, N, Z, A, m and p are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula (I) and to pharmaceutical compositions for treating such disorders which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).

  本发明涉及式1化合物及其药学上可接受的盐、前药和溶剂化物，其中R1、R3、R4、R11、N、Z、A、m和p的定义如本文所述。本发明还涉及通过给予式(I)化合物治疗哺乳动物中异常细胞生长的方法，以及包含式(I)化合物的用于治疗此类疾病的制药组合物。本发明还涉及制备式(I)化合物的方法。
• QUINAZOLINES AND PYRIDO[3,4-D]PYRIMIDINES AS RECEPTOR TYROSINE KINASE INHIBITORS
  申请人：Pfizer Products Inc.

  公开号：EP1636195A1

  公开（公告）日：2006-03-22
• US7585869B2
  申请人：——

  公开号：US7585869B2

  公开（公告）日：2009-09-08
• The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer
  作者：Blaise Lippa、Goss S. Kauffman、Joel Arcari、Tricia Kwan、Jinshan Chen、William Hungerford、Samit Bhattacharya、Xumiao Zhao、Courtney Williams、Jun Xiao、Leslie Pustilnik、Chunyan Su、James D. Moyer、Ling Ma、Mary Campbell、Stefanus Steyn

  DOI：10.1016/j.bmcl.2007.03.046

  日期：2007.6

  The synthesis and biological evaluation of potent and selective inhibitors of the erbB2 kinase is presented. Based on the 4-anilinoquinazoline chemotype, the syntheses of several new series of erbB2 inhibitors are described with quinazoline and pyrido[4,3-d]pyrimidine cores. The vast majority of these compounds are found to be >100x selective over the closely related EGFR kinase. Two lead compounds are further shown to have low clearance and moderate bioavailability in rat. (C) 2007 Elsevier Ltd. All rights reserved.